Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases.
about
Resveratrol and Cardiovascular DiseasesPhytochemical Compounds and Protection from Cardiovascular Diseases: A State of the ArtSIRT3 in Cardiac Physiology and DiseaseResveratrol Enhances Neuroplastic Changes, Including Hippocampal Neurogenesis, and Memory in Balb/C Mice at Six Months of AgeResveratrol attenuated estrogen-deficient-induced cardiac dysfunction: role of AMPK, SIRT1, and mitochondrial function.Mechanism of resveratrol-induced relaxation in the human gallbladder.Effects of resveratrol on drug- and carcinogen-metabolizing enzymes, implications for cancer prevention.Effects of levothyroxine replacement therapy on parameters of metabolic syndrome and atherosclerosis in hypothyroid patients: a prospective pilot studyResveratrol, in its natural combination in whole grape, for health promotion and disease managementChronic resveratrol reverses a mild angiotensin II-induced pressor effect in a rat model.Contribution of mitochondrial oxidative stress to hypertension.Resveratrol: How Much Wine Do You Have to Drink to Stay Healthy?Antidiabetic Effects of Resveratrol: The Way Forward in Its Clinical Utility.Postnatal resveratrol supplementation improves cardiovascular function in male and female intrauterine growth restricted offspringTherapeutic potential of resveratrol in heart failure.Resveratrol and derivatives for the treatment of atrial fibrillation.An overview of the efficacy of resveratrol in the management of ischemic heart disease.Prophylactic supplementation of resveratrol is more effective than its therapeutic use against doxorubicin induced cardiotoxicity.Maternal Macronutrient Consumption and the Developmental Origins of Metabolic Disease in the Offspring.Association of Neutrophil-Lymphocyte Ratio and the Presence of Noncalcified or Mixed Coronary Atherosclerotic Plaques.In Utero Origins of Hypertension: Mechanisms and Targets for Therapy.Resveratrol promotes differentiation of mouse embryonic stem cells to cardiomyocytes.Antioxidant effects of resveratrol in the cardiovascular system.Peripheral and Cerebral Resistance Arteries in the Spontaneously Hypertensive Heart Failure Rat: Effects of Stilbenoid Polyphenols.Resveratrol improves exercise performance and skeletal muscle oxidative capacity in heart failure.Disparate Effects of Stilbenoid Polyphenols on Hypertrophic Cardiomyocytes In Vitro vs. in the Spontaneously Hypertensive Heart Failure Rat.Mechanisms and therapeutic prospects of polyphenols as modulators of the aryl hydrocarbon receptor.Inflammation and metabolic cardiomyopathy.Cellular and Molecular Mechanisms of Diabetic Atherosclerosis: Herbal Medicines as a Potential Therapeutic Approach.Self-Nanoemulsifying Drug Delivery System for Resveratrol: Enhanced Oral Bioavailability and Reduced Physical Fatigue in Rats.Resveratrol enhances the inotropic effect but inhibits the proarrhythmic effect of sympathomimetic agents in rat myocardium.The anti-adhesive and anti-aggregatory effects of phenolics from Trifolium species in vitro.Effect of resveratrol and pterostilbene on aging and longevity.Anticancer effects of resveratrol in canine hemangiosarcoma cell lines.Advanced iron-overload cardiomyopathy in a genetic murine model is rescued by resveratrol therapy.AMPK and cardiac remodelling.Resveratrol for patients with chronic obstructive pulmonary disease: hype or hope?Potential benefits of phytochemicals against Alzheimer's disease.Resveratrol-Mediated Expression of KLF15 in the Ischemic Myocardium is Associated with an Improved Cardiac Phenotype.Effect of resveratrol on metabolic and cardiovascular function in male and female adult offspring exposed to prenatal hypoxia and a high-fat diet.
P2860
Q26752801-F4475ADC-13D0-4642-997F-B4A9C9D40691Q26778562-76B7439D-FBC9-429B-A256-F13140E6BAFDQ28076837-48384459-F736-4E34-B4E5-C37D07913943Q28551780-F006933D-FA8B-4FEF-AD94-50960E1F3655Q30379511-AB077E72-3C1A-42AF-BC8E-82BF2761F942Q33651451-3FDF2CEC-321F-487C-AE38-E0E4657C3686Q33771427-F0D4A1F7-EEDC-4BCA-A5CA-8613BDE7D070Q35187992-A9F04AC4-0D25-4549-8AA9-DC4C1E240A60Q36005933-D5D909F1-9157-49F3-A953-5ECFF61E5785Q36525791-6DC65DDC-D306-44AE-BCD5-05CA871DABB6Q36617393-6786C4F2-7E4B-49AD-8EE3-EECBCEB88B24Q37089803-1B85E554-5AB4-41C6-B4E9-7AB63722A850Q37512665-8D463F30-B75B-4741-AC92-FB35A9717157Q37609054-07356392-8298-463E-8F65-EB253ED79538Q38552981-6B3B842F-5EFE-41D5-A2AA-2BCD941D579AQ38553016-662731F6-2161-499B-91E0-DF096799CF45Q38557902-E048EBE2-9108-4F7B-83A0-203EC6DA230CQ38654368-3140404E-6DBD-4704-8D25-8DE3675BD397Q38661625-281294A2-B58E-4188-B32A-207E86E82AF0Q38691554-391C53D8-1525-4058-897E-D04C9369D8E5Q38737743-757EAFD2-9C17-4B55-94FD-D82219C592D3Q38768428-9FF15256-D2EE-4A33-9558-10B46307BFD0Q38802176-4C291657-4AC9-492F-957D-0331D8AD3BB3Q38926505-BEB6166A-65BF-4DA8-9CD2-CC005C672C5DQ38979963-05CCA1E6-C136-4628-9FEE-87A0DF891712Q38981344-7AE6C0E5-947E-4BD7-8042-469263B0AE4EQ39176010-350DF8B4-F76F-498C-88BA-124CB5045390Q39232024-AD082A59-F355-4352-8507-A57297FCD19FQ41528907-B95C82CA-507F-4055-BE5A-8554CEAB0EDDQ41661259-96716F92-7454-4F3B-9718-865CAE1F0F15Q42293112-03063101-6CCA-40DC-9C2F-440C72CE094FQ43079765-6F68D220-D278-4CFF-9470-BFA843EC0273Q47279730-70CD0935-62CD-4557-BF43-347AEBC89FCCQ47299200-AD61B441-542C-44FF-AE0C-6B0404AC9828Q47326291-B8C00925-FE89-461A-85F8-EADB0AB4BF51Q47369070-4948902F-6212-4F42-8F03-C437F9B280F5Q47563688-A04E1113-B558-403C-AAE4-7C37F53D7B0AQ48330952-B597599C-57DE-411F-8FA0-3A7E4C7B72B3Q50964118-08F4D4AE-CC77-413B-A773-2C15AF36BB70Q50971640-590DBD3C-AE91-428D-87A5-151C2BC8A10A
P2860
Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Preclinical and clinical evide ...... nt of cardiovascular diseases.
@en
type
label
Preclinical and clinical evide ...... nt of cardiovascular diseases.
@en
prefLabel
Preclinical and clinical evide ...... nt of cardiovascular diseases.
@en
P1476
Preclinical and clinical evide ...... ent of cardiovascular diseases
@en
P2093
Jason R B Dyck
P304
P356
10.1016/J.BBADIS.2014.10.016
P407
P577
2014-11-01T00:00:00Z